Recursion Pharmaceuticals, Inc. is upgraded to Buy, supported by promising REC-4881 data and strong institutional backing. REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
No sooner had John F. Kennedy’s granddaughter died of leukemia at age 35, than President Trump cast shade at her bereaved family via Truth Social. According to the Lehigh County coroner, a man has ...
Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Phynart Studio / Getty Images A call option, ...
Elvis Picardo is a regular contributor to Investopedia and has 25+ years of experience as a portfolio manager with diverse capital markets experience. Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is ...
Meet the Lehigh Valley’s first babies of 2026: 1 born 11 minutes past midnight, another at 1:11 a.m. on 1/1 Lehigh Valley Health Network welcomed its first baby of 2026 only 11 minutes after midnight, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback